LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 38,089 | 34,326 | 49,656 | 21,364 |
| Short-term investments | 132,569 | 61,904 | 66,294 | 117,643 |
| Accounts receivable, net | 11,779 | 2,384 | 2,334 | 2,183 |
| Inventory | 276 | 281 | 158 | 168 |
| Prepaid expenses and other current assets | 3,319 | 3,000 | 4,085 | 3,726 |
| Total current assets | 186,032 | 101,895 | 122,527 | 145,084 |
| Property and equipment, net | 1,753 | 1,863 | 1,981 | 2,132 |
| Goodwill | 44,543 | 44,543 | 44,543 | 44,543 |
| Operating lease right-of-use-assets | 7,123 | 7,318 | 7,508 | 4,456 |
| Restricted cash | 29,000 | 29,000 | 29,000 | 29,000 |
| Other assets | 368 | 368 | 368 | 368 |
| Total assets | 268,819 | 184,987 | 205,927 | 225,583 |
| Accounts payable | 2,996 | 3,083 | 3,797 | 5,899 |
| Deferred revenue | - | - | 4,303 | 17,456 |
| Accrued liabilities | 6,902 | 13,189 | 13,620 | 11,481 |
| Current portion of long-term debt | 0 | 4,595 | - | - |
| Total current liabilities | 9,898 | 20,867 | 21,720 | 34,836 |
| Long-term debt, net | 49,684 | 49,408 | 56,508 | 56,107 |
| Other long-term liabilities | 6,381 | 7,174 | 7,540 | 5,200 |
| Total liabilities | 65,963 | 77,449 | 85,768 | 96,143 |
| Series a convertible preferred stock 2,304,147 shares issued and none outstanding at march31, 2026 and december31, 2025 | 4 | - | - | - |
| Common stock, 0.001 par value 450,000,000 shares authorized 425,708,402 and 365,848,216 shares issued, respectively | 426 | 366 | 366 | 366 |
| Additional paid-in capital | 2,224,025 | 2,129,912 | 2,127,005 | 2,123,560 |
| Accumulated deficit | -2,018,626 | -2,017,583 | -2,002,054 | -1,989,285 |
| Accumulated other comprehensive (loss) income | -130 | 30 | 29 | -14 |
| Treasury stock, at cost, 1,933,747 and 2,381,939 shares, respectively | 2,843 | 5,187 | 5,187 | 5,187 |
| Total stockholders equity | 202,856 | 107,538 | 120,159 | 129,440 |
| Total liabilities and stockholders equity | 268,819 | 184,987 | 205,927 | 225,583 |